Chemotherapy-Induced Hepatotoxicity in HIV Patients

Human immunodeficiency virus (HIV) affects more than 37 million people globally, and in 2020, more than 680,000 people died from HIV-related causes. Recently, these numbers have decrease substantially and continue to reduce thanks to the use of antiretroviral therapy (ART), thus making HIV a chronic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Silvia Bressan, Alessandra Pierantoni, Saman Sharifi, Sergio Facchini, Vincenzo Quagliarello, Massimiliano Berretta, Monica Montopoli
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	drug-drug interactions hepatotoxicity HIV ART chemotherapy immunotherapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/b010a7fa48a24c93abf13f7460a87174
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b010a7fa48a24c93abf13f7460a87174
record_format	dspace
spelling	oai:doaj.org-article:b010a7fa48a24c93abf13f7460a871742021-11-25T17:08:20ZChemotherapy-Induced Hepatotoxicity in HIV Patients10.3390/cells101128712073-4409https://doaj.org/article/b010a7fa48a24c93abf13f7460a871742021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2871https://doaj.org/toc/2073-4409Human immunodeficiency virus (HIV) affects more than 37 million people globally, and in 2020, more than 680,000 people died from HIV-related causes. Recently, these numbers have decrease substantially and continue to reduce thanks to the use of antiretroviral therapy (ART), thus making HIV a chronic disease state for those dependent on lifelong use of ART. However, patients with HIV have an increased risk of developing some type of cancer compared to patients without HIV. Therefore, treatment of patients who are diagnosed with both HIV and cancer represents a complicated scenario because of the risk associated with drug–drug interaction (DDIs) and related toxicity. Selection of an alternative chemotherapy or ART or temporarily discontinuation of ART constitute a strategy to manage the risk of DDIs. Temporarily withholding ART is the less desirable clinical plan but risks and benefits must be considered in each scenario. In this review we focus on the hepatotoxicity associated with a simultaneous treatment with ART and chemotherapeutic drugs and mechanisms behind. Moreover, we also discuss the effect on the liver caused by the association of immunotherapeutic drugs, which have recently been used in clinical trials and also in HIV patients.Silvia BressanAlessandra PierantoniSaman SharifiSergio FacchiniVincenzo QuagliarelloMassimiliano BerrettaMonica MontopoliMDPI AGarticledrug-drug interactionshepatotoxicityHIVARTchemotherapyimmunotherapyBiology (General)QH301-705.5ENCells, Vol 10, Iss 2871, p 2871 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug-drug interactions hepatotoxicity HIV ART chemotherapy immunotherapy Biology (General) QH301-705.5
spellingShingle	drug-drug interactions hepatotoxicity HIV ART chemotherapy immunotherapy Biology (General) QH301-705.5 Silvia Bressan Alessandra Pierantoni Saman Sharifi Sergio Facchini Vincenzo Quagliarello Massimiliano Berretta Monica Montopoli Chemotherapy-Induced Hepatotoxicity in HIV Patients
description	Human immunodeficiency virus (HIV) affects more than 37 million people globally, and in 2020, more than 680,000 people died from HIV-related causes. Recently, these numbers have decrease substantially and continue to reduce thanks to the use of antiretroviral therapy (ART), thus making HIV a chronic disease state for those dependent on lifelong use of ART. However, patients with HIV have an increased risk of developing some type of cancer compared to patients without HIV. Therefore, treatment of patients who are diagnosed with both HIV and cancer represents a complicated scenario because of the risk associated with drug–drug interaction (DDIs) and related toxicity. Selection of an alternative chemotherapy or ART or temporarily discontinuation of ART constitute a strategy to manage the risk of DDIs. Temporarily withholding ART is the less desirable clinical plan but risks and benefits must be considered in each scenario. In this review we focus on the hepatotoxicity associated with a simultaneous treatment with ART and chemotherapeutic drugs and mechanisms behind. Moreover, we also discuss the effect on the liver caused by the association of immunotherapeutic drugs, which have recently been used in clinical trials and also in HIV patients.
format	article
author	Silvia Bressan Alessandra Pierantoni Saman Sharifi Sergio Facchini Vincenzo Quagliarello Massimiliano Berretta Monica Montopoli
author_facet	Silvia Bressan Alessandra Pierantoni Saman Sharifi Sergio Facchini Vincenzo Quagliarello Massimiliano Berretta Monica Montopoli
author_sort	Silvia Bressan
title	Chemotherapy-Induced Hepatotoxicity in HIV Patients
title_short	Chemotherapy-Induced Hepatotoxicity in HIV Patients
title_full	Chemotherapy-Induced Hepatotoxicity in HIV Patients
title_fullStr	Chemotherapy-Induced Hepatotoxicity in HIV Patients
title_full_unstemmed	Chemotherapy-Induced Hepatotoxicity in HIV Patients
title_sort	chemotherapy-induced hepatotoxicity in hiv patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b010a7fa48a24c93abf13f7460a87174
work_keys_str_mv	AT silviabressan chemotherapyinducedhepatotoxicityinhivpatients AT alessandrapierantoni chemotherapyinducedhepatotoxicityinhivpatients AT samansharifi chemotherapyinducedhepatotoxicityinhivpatients AT sergiofacchini chemotherapyinducedhepatotoxicityinhivpatients AT vincenzoquagliarello chemotherapyinducedhepatotoxicityinhivpatients AT massimilianoberretta chemotherapyinducedhepatotoxicityinhivpatients AT monicamontopoli chemotherapyinducedhepatotoxicityinhivpatients
_version_	1718412734267129856

Chemotherapy-Induced Hepatotoxicity in HIV Patients

Ejemplares similares